In ccRCC tumors that harbor a functional HIF1A gene, inhibition of HIF-1α, or of both HIF-1α and HIF-2α, might represent an alternative therapeutic strategy. This evidence concerns the gene EPAS1 and nonpapillary renal cell carcinoma.